本文選題：黃龍咳喘膠囊　切入點(diǎn)：慢性支氣管炎　出處：《中藥藥理與臨床》2017年05期 　論文類型：期刊論文

【摘要】：目的:黃龍咳喘膠囊治療老年慢性支氣管炎的臨床療效。方法:106例來自石河子大學(xué)醫(yī)學(xué)院第一附屬醫(yī)院的老年慢性支氣管炎患者(2015.8--2016.12)隨機(jī)原則分為對(duì)照組和觀察組,各53例。兩組均接受常規(guī)治療,觀察組另外給予黃龍咳喘膠囊。結(jié)果:10天為一個(gè)療程,治療3個(gè)療程后,觀察組療效(94.34%)明顯高于對(duì)照組(77.36%)。經(jīng)治療,兩組血清炎癥水平、血液流變學(xué)指標(biāo)均下降,血?dú)庵笜?biāo)得以改善,觀察組hs-CRP、TNF-ɑ、IL-8水平分別低于對(duì)照組(9.73±2.42)mg/L比(12.91±2.86)mg/L、(0.51±0.29)ng/ml比(0.92±0.35)ng/ml、(0.60±0.34)ng/ml比(1.05±0.39)ng/ml,觀察組Pa CO2和Pa O2均明顯優(yōu)于對(duì)照組(44.93±4.16)mm Hg比(50.27±4.47)mm Hg、(89.83±7.05)mm Hg比(81.27±6.72)mm Hg,觀察組全血粘度高切、全血粘度低切、血漿粘度分別低于對(duì)照組(4.59±0.41)m Pa·s比(5.16±0.50)m Pa·s、(7.83±0.60)m Pa·s比(8.95±0.71)m Pa·s、(1.57±0.12)m Pa·s比(1.83±0.14)m Pa·s。對(duì)照組不良反應(yīng)總發(fā)生率為11.32%,和觀察組9.43%比,差異無統(tǒng)計(jì)學(xué)意義。結(jié)論:黃龍咳喘膠囊可作為老年慢性支氣管炎的輔助用藥,其可增加慢性支氣管炎治療效果,改善患者血?dú)�、血液流變學(xué),降低炎癥,且較為安全。
[Abstract]:Objective: to evaluate the clinical efficacy of Huanglong Kechuan capsule in the treatment of senile chronic bronchitis. Methods: one hundred and six elderly patients with chronic bronchitis from the first affiliated Hospital of Shihezi University Medical College were randomly divided into two groups: control group and observation group. There were 53 cases in each group. Both groups received routine treatment. The observation group was given Huanglong Kechuan capsule in addition. Results after 3 courses of treatment, the therapeutic effect of the observation group was 94.34) significantly higher than that of the control group (77.360.The level of serum inflammation in the two groups was significantly higher than that in the control group. The levels of hs-CRP TNF-tir IL-8 in the observation group were significantly lower than those in the control group (9.73 鹵2.42 mg / L vs 12.91 鹵2.86 mg / L vs 0.92 鹵0.35 ng / ml vs 0.92 鹵0.35 ng / ml vs 1.05 鹵0.39 ng / ml, respectively). The CO2 and PaO2 in the observation group were significantly higher than those in the control group (44.93 鹵4.16 mm Hg vs 50.27 鹵4.47 mm Hg vs 81.27 鹵6.72 mg / ml), and the blood viscosity of the observation group was significantly higher than that of the control group (44.93 鹵4.16 mm Hg vs 50.27 鹵4.47 mm / L vs 81.27 鹵6.72 mm / ml). The whole blood viscosity was lower than that of the control group (4.59 鹵0.41mPa 路s vs 5.16 鹵0.50mPa 路s, 7.83 鹵0.60mPa 路s vs 8.95 鹵0.71mPa 路s vs 1.83 鹵0.12mPa 路s vs 1.83 鹵0.14mPa 路s, respectively). The total incidence of adverse reactions in the control group was 11.32, and that in the observation group was 9.43%. Conclusion: Huanglong Kechuan capsule can be used as an adjuvant drug for senile chronic bronchitis, which can increase the therapeutic effect of chronic bronchitis, improve blood gas, hemorheology, reduce inflammation, and is more safe.
【作者單位】： 石河子大學(xué)醫(yī)學(xué)院第一附屬醫(yī)院;
【分類號(hào)】：R259

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 段東印;自擬平喘湯治療慢性支氣管炎56例[J];新鄉(xiāng)醫(yī)學(xué)院學(xué)報(bào);2001年04期

2 王安川;偏方治慢性支氣管炎[J];中國民間療法;2002年12期

3 李建武;中藥治療慢性支氣管炎的體會(huì)[J];河北職工醫(yī)學(xué)院學(xué)報(bào);2003年03期

4 周志華,吳洲紅,戴曉英,吳伯庠;三伏膏治療慢性支氣管炎302例[J];中國中醫(yī)藥科技;2004年06期

5 何榮,張偉;從中醫(yī)藥構(gòu)成比看慢性支氣管炎的療效[J];遼寧中醫(yī)學(xué)院學(xué)報(bào);2005年01期

6 羅亞芳;;自擬止嗽方治療慢性支氣管炎42例療效觀察[J];中國民族民間醫(yī)藥;2013年12期

7 林求誠;高墀巖;;慢性支氣管炎標(biāo)證治療586例療效分析[J];中西醫(yī)結(jié)合雜志;1985年01期

8 熊正明;;慢性支氣管炎的防治[J];中西醫(yī)結(jié)合雜志;1985年08期

9 陳文岳;Q酶Ｒ，

本文編號(hào)：1606528